Trial in Extensive-Disease Small Cell Lung Cancer (ED-SCLC) Subjects Comparing Ipilimumab Plus Etoposide and Platinum Therapy to Etoposide and Platinum Therapy Alone

Authors
Category Primary study
Registry of Trialsclinicaltrials.gov
Year 2011
The purpose of the study is to determine whether the addition of Ipilimumab to Etoposide and Platinum therapy will extend the lives of patients with Extensive-Stage Disease Small Cell Lung Cancer (ED-SCLC) more than Etoposide and Platinum therapy alone.
Epistemonikos ID: fd1c7a566497a269e27dfb84de0342e6f50d49f1
First added on: Nov 04, 2020